Ventus Therapeutics - About the company
Ventus Therapeutics is a series C company based in Boston (United States), founded in 2019. It operates as a Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment. Ventus Therapeutics has raised $300M in funding from investors like Andreessen Horowitz, Qatar Investment Authority and Versant Ventures. The company has 369 active competitors, including 40 funded and 54 that have exited. Its top competitors include companies like Novartis, Catalent and Surrozen.
Company Details
- Website
- ventustx.com
- Social
- Email ID
- *****@ventustx.com
- Registered Address
- Rīga, Vestienas iela 2
Key Metrics
Founded Year
2019
Location
Boston, United States
Stage
Series C
Total Funding
$300M in 3 rounds
Latest Funding Round
Investors
Ranked
12th among 369 active competitors
Employee Count
65 as on Mar 31, 2026
Legal entities associated with Ventus Therapeutics
Ventus Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
VENTUS CIN: 40003819098 , Latvia, Active | Apr 18, 2006 | $11K (As on Dec 31, 2024) | 1 (As on Dec 31, 2022) | - |
Sign up to download Ventus Therapeutics' company profile
Ventus Therapeutics's funding and investors
Ventus Therapeutics has raised a total funding of $300M over 3 rounds. Its first funding round was on Nov 18, 2019. Its latest funding round was a Series C round on Feb 07, 2022 for $*****. 11 investors participated in its latest round. Ventus Therapeutics has 12 institutional investors.
Here is the list of recent funding rounds of Ventus Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 07, 2022 | 7640086 | Series C | 2130225 | 4857379 | 6863117 | 7312287 |
Mar 31, 2021 | 5699891 | Series B | 6648004 | 6480959 | 1055849 | |
Nov 18, 2019 | 3425392 | Series A | 8477040 | 1038937 |
Access funding benchmarks and valuations. Sign up today!View details of Ventus Therapeutics's funding rounds and investors
Ventus Therapeutics' founders and board of directors
Founder? Claim ProfileVentus Therapeutics' employee count trend
Ventus Therapeutics has 65 employees as of Mar 26. Here is Ventus Therapeutics's employee count trend over the years:
Uncover Ventus Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Ventus Therapeutics's Competitors and alternates
Top competitors of Ventus Therapeutics include Novartis, Catalent and Surrozen. Here is the list of Top 10 competitors of Ventus Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Novartis 1996, Basel (Switzerland), Public | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 | |
2nd | Catalent 2007, Somerset (United States), Acquired | Provider of development, manufacturing, and packaging solutions for medicines and supplements | - | 68/100 | |
3rd | Surrozen 2016, San Francisco (United States), Public | Pioneering targeted regenerative antibodies to repair tissue and restore organ function | $133M | 66/100 | |
4th | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | - | 62/100 | ||
5th | BioFactura 2004, Frederick (United States), Series B | Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs | $7.8M | 56/100 | |
6th |  Full-Life Technologies 2021, Shanghai (China), Series C | Provider of discovery, development, production, and logistics services for of nuclear medicines | $200M | 56/100 | |
7th |  Acclinate 2020, Birmingham (United States), Series A | Provider of clinical trial services to biopharma sector | $12M | 54/100 | |
8th | Tirupati Medicare 1980, Paonta Sahib (India), Series B | Contract manufacturer of pharmaceutical products | $51.5M | 54/100 | |
9th |  AmplifyBio 2021, Hilliard (United States), Deadpooled | Provider of contract research, development, and manufacturing services for biologic drugs | $230M | 54/100 | |
10th | WuXi Biologics 2008, Shanghai (China), Public | Developer and manufacturer for protein therapeutics | - | 52/100 | |
12th |  Ventus Therapeutics 2019, Boston (United States), Series C | Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment | $300M | 51/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ventus Therapeutics's competitors? Click here to see the top ones
Ventus Therapeutics's Investments and acquisitions
Ventus Therapeutics has made no investments or acquisitions yet.
News related to Ventus Therapeutics
Filter this listMedia has covered Ventus Therapeutics for a total of 3 events in the last 1 year, 3 of them have been about company updates.
•
•
•
•
•
Ventus starts Phase 2a trial of oral Parkinson's drug VENT-02.Business Wire•Mar 10, 2025•Ventus Therapeutics
•
Ventus Therapeutics Appoints Mona Kotecha, M.D., as Chief Medical OfficerBusiness Wire•Feb 19, 2025•Ventus Therapeutics
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Ventus Therapeutics
Explore our recently published companies
- Bakedts Company - St. Louis based, 2009 founded, Unfunded company
- Bad Wreck Media Company - Los Angeles based, Unfunded company
- Snowboard Shop - 2006 founded, Unfunded company
- Axiom360hd - Germantown based, 2018 founded, Unfunded company
- B1 Gear - Newport Beach based, 2021 founded, Unfunded company
- Sea Trials - Baltimore based, 2018 founded, Unfunded company
